Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort - 22/07/20
Doi : 10.1016/j.jaci.2020.01.039
Annette T. Hastie, PhD a 
, David T. Mauger, PhD b, Loren C. Denlinger, MD, PhD c, Andrea Coverstone, MD d, Mario Castro, MD d, Serpil Erzurum, MD e, Nijar Jarjour, MD c, Bruce D. Levy, MD f, Deborah A. Meyers, PhD g, Wendy C. Moore, MD a, Brenda Phillips, MS b, Sally E. Wenzel, MD h, John V. Fahy, MD i, Elliot Israel, MD f, Eugene R. Bleecker, MD g
the
, David T. Mauger, PhD b, Loren C. Denlinger, MD, PhD c, Andrea Coverstone, MD d, Mario Castro, MD d, Serpil Erzurum, MD e, Nijar Jarjour, MD c, Bruce D. Levy, MD f, Deborah A. Meyers, PhD g, Wendy C. Moore, MD a, Brenda Phillips, MS b, Sally E. Wenzel, MD h, John V. Fahy, MD i, Elliot Israel, MD f, Eugene R. Bleecker, MD gthe
NHLBI SARP 3 Investigators
Allison Crosby-Thompson, Carrie Nettles, Angeles Cinelli, Meghan Le, Joy Lawrence, Donna Liu, Jenelle Mock, Danica Klaus, Gina Crisafi, Regina Smith, Jeff Krings, Rachel Weaver, Daniel Nguyen, Kristin McIntire, Sara Baicker-McKee, Annabelle Charbit, John Trudeau, Heather Floerke, Susan Foster, Brian Rector, Huiqing Yin-Declue, Dr Patricia Noel, Dr Tom Croxton, Dr Robert Smith
a Wake Forest University School of Medicine, Winston-Salem, NC
b Penn State College of Medicine, Hershey, Pa
c University of Wisconsin-Madison, Madison, Wis
d Washington University School of Medicine, St Louis, Mo
e Cleveland Clinic, Cleveland, Ohio
f Brigham and Womens Hospital, Boston, Mass
g University of Arizona College of Medicine, Tucson, Ariz
h University of Pittsburgh, Pittsburgh, Pa
i University of California San Francisco, Calif
| The research by the principal and coprincipal investigators was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) Severe Asthma Research Program: E.R.B. (principal investigator [PI], grant no. U10 HL109164), M.C. (PI, grant no. U10 HL109257), J.V.F. (PI, grant no. U10 HL109146), E.I. and B.D.L. (co-PIs, grant no. U10 HL109172), B. M. Gaston, S.C.E., and W. G. Teague (PI and Co-PIs, grant no. U10 HL109250), N.N.J. (PI, U10 HL109168), S.E.W. (PI, U10 HL109152), and D.T.M. (PI, U10 HL109086). Industry partnerships also provided additional support: AstraZeneca, Boehringer Ingelheim, Genetech, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi, and Teva. Spirometers used in SARP III were provided by nSpire Health (Longmont, Colo). |
|
| Disclosure of potential conflict of interest: A. T. Hastie reports grants from the National Institutes of Health (NIH), Genentech, and GlaxoSmithKline (GSK) during the conduct of the study. D. T. Mauger reports grant support from the NIH, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and Teva. L. C. Denlinger has grants from the NIH/National Heart, Lung, and Blood Institute (NHLBI) and has consulted with AstraZeneca and Sanofi-Regeneron during the conduct of the study; the extension of the longitudinal phase of the SARP cohort has also been supported by AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and Teva. M. Castro receives university grant funding from the NIH, the American Lung Association, and Patient-Centered Outcomes Research Institute (PCORI); pharmaceutical grant funding from AstraZeneca, Chiesi, Novartis, GSK, and Sanofi-Aventis; consultant fees for Genentech, Theravance, VIDA, Teva, and Sanofi-Aventis; is a speaker for AstraZeneca, Genentech, GSK, Regeneron, Sanofi, & Teva; and receives royalties from Elsevier. S. Erzurum reports grants from the NIH, during the conduct of the study; and is Chair of the American Board of Internal Medicine (ABIM) Pulmonary Disease Board. N. Jarjour has grants from NIH/NHLBI and has consulted with AstraZeneca and Boehringer Ingelheim, and during the extension of the longitudinal phase of the SARP cohort has also been supported, in part, by AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and Teva. B. D. Levy reports grants from the NIH during the conduct of the study; other fees from Nocion Therapeutics and Entrinsic Health; grants and personal fees from Sanofi; personal fees from Pieris Pharmaceuticals, Novartis, AstraZeneca, Corbus Pharmaceuticals, Gossamer Bio, Metera Pharmaceuticals, and Teva; and grants from Samsung Research America outside the submitted work. W. C. Moore reports grants from the NIH/NHLBI, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and Teva during the conduct of the study; grants and personal fees from AstraZeneca and Sanofi-Regeneron; and grants from Boehringer Ingelheim, GSK, Novartis, Gossamer, and Cumberland Pharmaceuticals outside the submitted work. B. Phillips reports grants from the NIH, Boehringer Ingelheim, Teva, AstraZeneca, GSK, Sanofi, and Genentech during the conduct of the study. S. E.Wenzel reports grants from the NIH and personal fees from AstraZeneca; grants and personal fees from GSK during the conduct of the study; and grants and personal fees from Sanofi-Regeneron, grants from Boehringer Ingelheim, Novartis, and Teva, and personal fees from Pieris outside the submitted work. J. V. Fahy reports grants from the NIH/NHLBI and Boehringer Ingelheim during the conduct of the study; personal fees from Boehringer Ingelheim, Pieris, Arrowhead Pharmaceuticals, and Gossamer outside the submitted work; in addition, J. V. Fahy has a patent US20110123530A1 “Compositions and methods for treating and diagnosing asthma” issued, a patent WO2014153009A2 “Thiosaccharide mucolytic agents” issued, and a patent pending WO2017197360 “CT Mucus Score”—A new scoring system that quantifies airway mucus impaction using CT lung scans. E. Israel reports personal fees from AstraZeneca, Biometry, Entrinsic Health Solutions, Equillium, Genentech, GSK, Merck, Novartis, 4D Pharma, Pneuma Respiratory, Regeneron Pharmaceuticals, Sanofi Genzyme, Sienna Biopharmaceutical, Teva Specialty Pharmaceuticals, and Vitaeris, Inc; grants from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Merck, Novartis, Sanofi, Teva, and Vifor-Pharma; nonfinancial support from Circassia, Boehringer Ingelheim, Genentech, GSK, Merck, Teva Specialty Pharmaceuticals, and Vifor-Pharma; and other fees from Vorso Corp, outside the submitted work. E. R. Bleecker reports other fees from NIH grant; clinical trials through his employer, Wake Forest School of Medicine and University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Johnson and Johnson (Janssen), Novartis, Regeneron, and Sanofi Genzyme; and personal fees also serving as a paid consultant for AztraZeneca, MedImmune, Boehringer Ingelheim, GSK, Novartis, Regeneron, and Sanofi Genzyme outside the submitted work. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 146 - N° 1
P. 222-226 - juillet 2020 Retour au numéro
Article précédent
- Serum folate metabolites, asthma, and lung function in a nationwide US study
- Yueh-Ying Han, Erick Forno, Franziska Rosser, Juan C. Celedón
- An academic allergy unit during COVID-19 pandemic in Italy
- Giacomo Malipiero, Giovanni Paoletti, Francesca Puggioni, Francesca Racca, Sebastian Ferri, Antonino Marsala, Ornella Leoncini, Monica Porli, Gabriella Pieri, Giorgio Walter Canonica, Enrico Heffler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?